Notícias

Biogen (NASDAQ:BIIB) reported stronger-than-expected second-quarter results on Wednesday, with revenue and adjusted earnings exceeding Wall Street forecasts as its expanding portfolio of growth products continued to offset weakness in its legacy multiple sclerosis business. The biotechnology company posted revenue of $2.

Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.

Biogen (BIIB) delivered earnings and revenue surprises of +18.42% and +9.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.

Investing.com -- Biogen reported second-quarter revenue and adjusted profit above analysts’ estimates on Wednesday, helped by 24% growth in its Growth Portfolio and stronger revenue from recently acquired products, although sales of its Alzheimer’s drug Leqembi narrowly missed expectations.

Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.

Biogen’s second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjusted earnings forecast.

Today Federal Reserve meeting: Fed Chairman Kevin Warsh will hold a press conference at 2:30 p.m. ET, following the FOMC interest-rate decision at 2 p.m. Earnings (a.m): Procter & Gamble, Humana, L3Harris, Biogen, General Dynamics, Teva Pharmaceuticals, Airbus Earnings (p.

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for.

HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.

Today Earnings (a.m.): Coca-Cola, UPS, Boeing, Sherwin-Williams, Hilton, Centene, PayPal, S&P Global Earnings (p.m.): Visa, Ford Motor, Mondelez International, Waste Management, PPG Industries, Bloom Energy, Avis Budget, Seagate Technology Economic data: Consumer confidence index, Johnson Redbook retail sales index, U.

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.

BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first

By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide […] The post Slate Medicines Appoints Mark W. Hahn to Board of Directors appeared first on ExecEdge.

Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.

Data released by Biogen at AAIC26 appears to have spooked investors, with an 8.17% drop in share price.

Biogen (BIIB) is back in focus after fresh Alzheimer’s data, including new real world results for LEQEMBI and Phase 2 findings for tau targeting candidate diranersen, gave investors more information on the company’s neurology pipeline. See our latest analysis for Biogen. Despite the positive Alzheimer’s headlines, Biogen’s 1 day share price return was down 8.17% and the 7 day share price return was down 6.68%. However, the year to date share price return of 7.95% and 1 year total shareholder...

Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern. The company presented the update dur

Biogen’s mid-stage trial of diranersen did not meet its main goal of showing a clear relationship between higher doses and better results.

The presentation on Biogen’s experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects. Instead, Biogen stock is down 6%, to $197. Tuesday’s presentation on the drug diranersen, at London’s Alzheimer’s Association International Conference, left attendees confused about what to conclude from Biogen’s Phase 2 study known as CELIA.

The mid-stage study missed its primary goal, and the drug's lowest dose outperformed higher doses in ways the company cannot yet explain

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.

Biogen stock was down more than 8% Tuesday—on pace for its largest drop since 2020—after the company's experimental Alzheimer's drug failed to perform better on a key measure than drugs already on the market. On a standard dementia scale, patients taking Biogen’s experimental drug diranersen saw a 26% slowing in the rate of cognitive decline, roughly in line with the company’s drug Leqembi. Diranersen, which failed to meet its primary goal in a clinical trial in May, did succeed in cutting a protein called tau in patients' spinal fluid by as much as 65%, according to data presented Tuesday at the Alzheimer's Association International Conference.

Investing.com -- Biogen Inc. (NASDAQ:BIIB) shares fell nearly 9% following the Phase 2 CELIA readout of its highly anticipated Alzheimer’s therapy, diranersen. While the drug achieved a major scientific milestone by robustly clearing tau pathology, an unexpected inverse dose response—where the lowest dose performed the best—left Wall Street analysts confused and triggered a sell-off. Diranersen missed its primary endpoint: proving a dose-dependent response on the CDR-SB, a key measure of cogniti

Eisai and Biogen recently received FDA approval for LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector initiation dose that allows adults with early Alzheimer’s disease to start and continue treatment at home instead of relying solely on intravenous infusions in clinics. This at-home option, supported by data showing exposure equivalent to IV dosing and high ease-of-use ratings from patients and care partners, could meaningfully change how Alzheimer’s therapies are delivered and accessed...